Akeso, Inc. (4RY.F)

5,90 +0,15 (+2,61%) Alla chiusura: 09:59AM CEST

Akeso, Inc.

No. 6, Shennong Road
Torch Development Zone
Zhongshan 528437
China
86 76 0898 73998
https://www.akesobio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 2.778

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Yu Xia Ph.D.	Founder, CEO, President & Chairwoman	837,6k	N/D	1967
Dr. Baiyong Li Ph.D.	Co-Founder, Executive VP, CSO & Executive Director	643,99k	N/D	1969
Mr. Zhongmin Wang Ph.D.	Co-Founder, Senior VP & Executive Director	461,68k	N/D	1969
Mr. Yu Xia Ph.D.	Senior VP & Executive Director	500,07k	N/D	1971
Dr. Peng Zhang Ph.D.	Co-Founder & Senior VP	N/D	N/D	N/D
Dr. Xinfeng Zhang	Senior Vice President	N/D	N/D	N/D
Mr. Wenjun Shi	Senior Vice President	N/D	N/D	N/D
Dr. Mingxiu Hu Ph.D.	Senior Vice President	N/D	N/D	N/D
Dr. Charlie Zhang Ph.D.	Senior Vice President	N/D	N/D	N/D
Dr. Jing Min Ph.D.	Senior Vice President	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin's lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors. In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals; AstraZeneca Pharmaceuticals; Summit Therapeutics Inc.; and Shenzhen Chipscreen Biosciences Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.

Governance aziendale

L'ISS Governance QualityScore di Akeso, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.